These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24895814)

  • 1. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
    Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
    Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    Ishii M; Itano O; Morinaga J; Shirakawa H; Itano S
    PLoS One; 2022; 17(4):e0266707. PubMed ID: 35452492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
    Tani S; Murata S; Tamura M; Fukunaga K; Morita M; Hirata Y; Iida H; Kakuno A; Nishigami T; Yamanaka N
    Nihon Shokakibyo Gakkai Zasshi; 2011 Nov; 108(11):1892-901. PubMed ID: 22056711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
    J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
    Nishizawa T; Higuchi H; Takaishi H; Iizuka H; Izumiya M; Yamagishi Y; Hisamatsu T; Suzuki H; Masaoka T; Iwasaki E; Nagata H; Hibi T
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1657-9. PubMed ID: 17108736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.
    Lin Z; Zou X; Hu X; Huang D; Chen Y; Lin J; Li X; Zhang J
    Sci Rep; 2024 Oct; 14(1):23961. PubMed ID: 39397104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
    Kasai K; Kooka Y; Suzuki Y; Suzuki A; Oikawa T; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Takikawa Y
    Ann Surg Oncol; 2014 Oct; 21(11):3638-45. PubMed ID: 24817369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
    Huang P; Huang X; Zhou Y; Yang G; Sun Q; Shi G; Chen Y
    Can J Gastroenterol Hepatol; 2022; 2022():9680933. PubMed ID: 36199981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
    Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
    Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma].
    Zhou BJ; Wang WS; Yin Y; Yang J; Zhu XL; Ni CF
    Zhonghua Nei Ke Za Zhi; 2024 Aug; 63(8):769-775. PubMed ID: 39069865
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined High-Dose Radiotherapy with Sequential Gemcitabine-Cisplatin Based Chemotherapy Increase the Resectability and Survival in Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma: A Multi-institutional Cohort Study.
    Im JH; Yu JI; Kim TH; Kim TG; Kim JW; Seong J
    Cancer Res Treat; 2024 Jul; 56(3):838-846. PubMed ID: 38186240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the efficacy and safety of hepatic arterial infusion chemotherapy for unresectable hepatitis B-related intrahepatic cholangiocarcinoma].
    He MR; Zheng ZK; Wu TQ; Chen MS; Zhou ZG
    Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):309-315. PubMed ID: 38432672
    [No Abstract]   [Full Text] [Related]  

  • 14. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
    Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma.
    Ni JY; Sun HL; Guo GF; Zhou X; Wei JX; Xu LF
    Int Immunopharmacol; 2024 Oct; 140():112872. PubMed ID: 39121605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
    Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
    Nooijen LE; Franken LC; Belkouz A; Oulad Abdennabi I; Besselink MG; Busch OR; Swijnenburg RJ; Klümpen HJ; Erdmann JI
    Am J Clin Oncol; 2021 Oct; 44(10):526-532. PubMed ID: 34469345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhao R; Zhou J; Miao Z; Xiong X; Wei W; Li S; Guo R
    Front Immunol; 2024; 15():1397827. PubMed ID: 38799453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.